Suboptimal response following intradermal hepatitis B vaccine in infants

Jacqueline S. Coberly, Timothy Townsend, John Repke, Howard Fields, Harold Margolis, Neal A. Halsey

Research output: Contribution to journalArticle

Abstract

Two hundred and twenty-five infants were randomly assigned to receive 2 μg of plasma-derived hepatitis B vaccine (Heptavax) intradermally (ID-2), 10 μg intramuscularly (IM-10), or 2 μg intramuscularly (IM-2) in the deltoid region at birth, 2 and 4 months. At 6 months, ID-2 infants were less likely to have developed ≥ 10 mIU ml-1 of antibody to hepatitis B surface antigen (anti-HBs) than IM-10 infants (91 versus 100%; p=0.02) and had a lower geometric mean concentration of anti-HBs (312 mIU ml- versus 2248 mIU ml-1; p < 0.01). At 6 months IM-10 infants had significantly lower mean weights and lengths than infants receiving 2 μg doses of vaccine. Intramuscular administration of 2 μg and 10 μg doses of Heptavax in the deltoid of young infants was well tolerated and effective; however, intradermal administration of Heptavax provided no immunological benefit over intramuscular administration and resulted in significantly higher rates of induration and persistent hyperpigmentation. Intramuscular immunization at birth, 2 and 4 months is an acceptable, effective alternative schedule for immunizing infants.

Original languageEnglish (US)
Pages (from-to)984-987
Number of pages4
JournalVaccine
Volume12
Issue number11
DOIs
StatePublished - 1994

    Fingerprint

Keywords

  • Hepatitis B vaccine
  • infants
  • response

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Coberly, J. S., Townsend, T., Repke, J., Fields, H., Margolis, H., & Halsey, N. A. (1994). Suboptimal response following intradermal hepatitis B vaccine in infants. Vaccine, 12(11), 984-987. https://doi.org/10.1016/0264-410X(94)90332-8